Trial Profile
Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Verteporfin (Primary)
- Indications Choroidal neovascularisation; Degenerative myopia
- Focus Therapeutic Use
- Acronyms FIDELIO
- 05 Nov 2013 New trial record